EGFR and non-small cell lung carcinoma: Oral targeted therapy with EGFR tyrosine kinase inhibitors (TKIs) became the first-line treatment for patients with metastatic and unresectable NSCLC with activating EGFR mutations since the late 2000s [4,5,6].